<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Abstract Human adenovirus (HAdV) is the most common cause of" exact="infectious" post="conjunctivitis, accounting for up to 75% of all conjunctivitis"/>
 <result pre="of infectious conjunctivitis, accounting for up to 75% of all" exact="conjunctivitis" post="cases and affecting people of all ages and demographics."/>
 <result pre="affecting people of all ages and demographics. In addition to" exact="ocular" post="complications, it can cause systemic infections in the form"/>
 <result pre="and demographics. In addition to ocular complications, it can cause" exact="systemic" post="infections in the form of gastroenteritis, respiratory disease, and"/>
 <result pre="demographics. In addition to ocular complications, it can cause systemic" exact="infections" post="in the form of gastroenteritis, respiratory disease, and dissemination"/>
 <result pre="it can cause systemic infections in the form of gastroenteritis," exact="respiratory" post="disease, and dissemination in immunocompromised individuals. HAdV causes lytic"/>
 <result pre="respiratory disease, and dissemination in immunocompromised individuals. HAdV causes lytic" exact="infection" post="of the mucoepithelial cells of the conjunctiva and cornea,"/>
 <result pre="cells of the conjunctiva and cornea, as well as latent" exact="infection" post="of lymphoid and adenoid cells. Epidemic keratoconjunctivitis (EKC) is"/>
 <result pre="as well as latent infection of lymphoid and adenoid cells." exact="Epidemic" post="keratoconjunctivitis (EKC) is the most severe ocular manifestation of"/>
 <result pre="well as latent infection of lymphoid and adenoid cells. Epidemic" exact="keratoconjunctivitis" post="(EKC) is the most severe ocular manifestation of HAdV"/>
 <result pre="and adenoid cells. Epidemic keratoconjunctivitis (EKC) is the most severe" exact="ocular" post="manifestation of HAdV infection, in which the presence of"/>
 <result pre="have the tendency to recur and may lead to long-term" exact="visual" post="disability. HAdV persistence and dissemination are linked to sporadic"/>
 <result pre="solutions should be proffered to handle the challenges associated with" exact="viral" post="persistence and dissemination. Several treatment modalities have been investigated,"/>
 <result pre="not only mitigate symptoms but reduce the course of the" exact="infection" post="and prevent the risk of long-term complications. These options"/>
 <result pre="and prevent the risk of long-term complications. These options include" exact="systemic" post="and topical antivirals, in-office povidone-iodine irrigation (PVI), immunoglobulin-based therapy,"/>
 <result pre="are warranted to reduce the economic burden and potential long-term" exact="visual" post="debilitation in affected patients. This review will focus on"/>
 <result pre="and future trends in prophylactic and therapeutic modalities for adenoviral" exact="keratoconjunctivitis" post="will be discussed. Keywords human adenovirus adenoviral keratoconjunctivitis antivirals"/>
 <result pre="for adenoviral keratoconjunctivitis will be discussed. Keywords human adenovirus adenoviral" exact="keratoconjunctivitis" post="antivirals immunotherapy povidone-iodine viral dissemination fig-count: table-count: ref-count: page-count:"/>
 <result pre="be discussed. Keywords human adenovirus adenoviral keratoconjunctivitis antivirals immunotherapy povidone-iodine" exact="viral" post="dissemination fig-count: table-count: ref-count: page-count: Introduction Human adenovirus (HAdV)"/>
 <result pre="Introduction Human adenovirus (HAdV) is the most common cause of" exact="infection" post="to the ocular surface, accounting for up to 75%"/>
 <result pre="(HAdV) is the most common cause of infection to the" exact="ocular" post="surface, accounting for up to 75% of conjunctivitis cases.1"/>
 <result pre="to the ocular surface, accounting for up to 75% of" exact="conjunctivitis" post="cases.1 The most common presentation is pharyngoconjunctival fever (PCF),"/>
 <result pre="to 75% of conjunctivitis cases.1 The most common presentation is" exact="pharyngoconjunctival fever" post="(PCF), which often occurs in children and manifests clinically"/>
 <result pre="with fever, pharyngitis, rhinitis, follicular conjunctivitis, and regional lymphoid hyperplasia.2" exact="Epidemic" post="keratoconjunctivitis (EKC) is the most severe ocular form and"/>
 <result pre="fever, pharyngitis, rhinitis, follicular conjunctivitis, and regional lymphoid hyperplasia.2 Epidemic" exact="keratoconjunctivitis" post="(EKC) is the most severe ocular form and is"/>
 <result pre="regional lymphoid hyperplasia.2 Epidemic keratoconjunctivitis (EKC) is the most severe" exact="ocular" post="form and is distinguished by its ability to invade"/>
 <result pre="to invade the corneal epithelium, ranging in presentation from a" exact="keratitis" post="to persistent and recurrent subepithelial infiltrates (SEIs). HAdV is"/>
 <result pre="epithelium, ranging in presentation from a keratitis to persistent and" exact="recurrent" post="subepithelial infiltrates (SEIs). HAdV is highly contagious due to"/>
 <result pre="hostâ€™s immune system. It is distinguished from other types of" exact="conjunctivitis" post="in that it often involves the cornea, with potentially"/>
 <result pre="in that it often involves the cornea, with potentially devastating" exact="visual" post="complications. These features contribute to a heavy economic burden"/>
 <result pre="of a standard treatment protocol.1 In addition to the potential" exact="ocular" post="manifestations of this virus, HAdV infections have the propensity"/>
 <result pre="addition to the potential ocular manifestations of this virus, HAdV" exact="infections" post="have the propensity to manifest systemically, in cases such"/>
 <result pre="risk in immunocompromised individuals. Despite the detrimental effect that HAdV" exact="infections" post="pose, there has yet to be an FDA-approved drug"/>
 <result pre="management difficult. Even following the active phase of the disease," exact="viral" post="persistence and reactivation may occur. Oral and topical antivirals"/>
 <result pre="solutions, but problems with efficacy, bioavailability, and therapeutic profiles have" exact="limited" post="their use. With regards to EKC, topical disinfection during"/>
 <result pre="and future trends in prophylactic and therapeutic modalities for adenoviral" exact="keratoconjunctivitis" post="will be discussed. Virology HAdV belongs to the genus"/>
 <result pre="consists of 7 groups classified through genomic sequence analysis.3 Adenoviral-based" exact="ocular" post="surface infections are attributed to several subtypes of Group"/>
 <result pre="7 groups classified through genomic sequence analysis.3 Adenoviral-based ocular surface" exact="infections" post="are attributed to several subtypes of Group B and"/>
 <result pre="Adenoviral-based ocular surface infections are attributed to several subtypes of" exact="Group B" post="and D HAdV. Generally, these viruses bind CD46, a"/>
 <result pre="made possible through the interaction between adenoviral fiber protein and" exact="primary" post="host cellular receptors such as CD46, sialic acid, and"/>
 <result pre="and acidification of the endosome, triggering conformational changes to the" exact="viral" post="capsid. This process culminates in the release of viral"/>
 <result pre="the viral capsid. This process culminates in the release of" exact="viral" post="DNA genome into the host nucleus, where viral replication"/>
 <result pre="release of viral DNA genome into the host nucleus, where" exact="viral" post="replication occurs.2,7-9 Challenges HAdV causes a lytic infection of"/>
 <result pre="nucleus, where viral replication occurs.2,7-9 Challenges HAdV causes a lytic" exact="infection" post="of the mucoepithelial cells of the conjunctiva and cornea"/>
 <result pre="of the conjunctiva and cornea as well as a latent" exact="infection" post="of lymphoid and adenoid cells.10 Members of Groups B"/>
 <result pre="of Groups B and D HAdV cause both GIT and" exact="ocular" post="infections. See Table 1 for the subtypes of Group"/>
 <result pre="and ocular infections. See Table 1 for the subtypes of" exact="Group B" post="and D HAdV.11,12 HAdV type 3, 7, and 21"/>
 <result pre="for the subtypes of Group B and D HAdV.11,12 HAdV" exact="type 3," post="7, and 21 of Group B can cause keratoconjunctivitis,"/>
 <result pre="and D HAdV.11,12 HAdV type 3, 7, and 21 of" exact="Group B" post="can cause keratoconjunctivitis, urinary tract infection, respiratory infection, and"/>
 <result pre="3, 7, and 21 of Group B can cause keratoconjunctivitis," exact="urinary tract infection," post="respiratory infection, and GIT infection. Group D HAdV can"/>
 <result pre="21 of Group B can cause keratoconjunctivitis, urinary tract infection," exact="respiratory" post="infection, and GIT infection. Group D HAdV can also"/>
 <result pre="cause keratoconjunctivitis, urinary tract infection, respiratory infection, and GIT infection." exact="Group D" post="HAdV can also cause both ocular and GIT infection."/>
 <result pre="and GIT infection. Group D HAdV can also cause both" exact="ocular" post="and GIT infection. Some group B HAdV subtypes infect"/>
 <result pre="and GIT infection. Some group B HAdV subtypes infect the" exact="respiratory" post="tract. Group B HAdV including type 3, 7, 14,"/>
 <result pre="infection. Some group B HAdV subtypes infect the respiratory tract." exact="Group B" post="HAdV including type 3, 7, 14, and 21 have"/>
 <result pre="HAdV subtypes infect the respiratory tract. Group B HAdV including" exact="type 3," post="7, 14, and 21 have been associated with acute"/>
 <result pre="type 3, 7, 14, and 21 have been associated with" exact="acute" post="respiratory distress (ARD) outbreaks.2,12 HAdV types that cause ARD"/>
 <result pre="3, 7, 14, and 21 have been associated with acute" exact="respiratory" post="distress (ARD) outbreaks.2,12 HAdV types that cause ARD are"/>
 <result pre="through aerosolized droplets. It is important to note that both" exact="respiratory" post="droplets and the fecal-oral transmission route from individuals with"/>
 <result pre="respiratory droplets and the fecal-oral transmission route from individuals with" exact="acute" post="adenoviral infection, or even post-infection adenoviral shedding, play an"/>
 <result pre="transmission dynamics of HAdV infections.2,13Table 1 Overview of Subtypes of" exact="Group B" post="and D HAdV with Sites of Infection Group HAdV"/>
 <result pre="Subtypes of Group B and D HAdV with Sites of" exact="Infection" post="Group HAdV Subtypes Site of Infection Group B HAdV"/>
 <result pre="HAdV with Sites of Infection Group HAdV Subtypes Site of" exact="Infection" post="Group B HAdV 3, 7, 11, 14, 16, 21,"/>
 <result pre="with Sites of Infection Group HAdV Subtypes Site of Infection" exact="Group B" post="HAdV 3, 7, 11, 14, 16, 21, 34, 35,"/>
 <result pre="35, 50, 55, 66, 68, and 76â€“79 Conjunctiva, urinary tract," exact="respiratory" post="tract, and gastrointestinal tract Group D HAdV 8, 9,"/>
 <result pre="and 76â€“79 Conjunctiva, urinary tract, respiratory tract, and gastrointestinal tract" exact="Group D" post="HAdV 8, 9, 10, 13, 15, 17, 19, 20,"/>
 <result pre="58â€“60, 63â€“65, 67, 69â€“75, 80â€“88, and 90â€“103 Cornea, urinary tract," exact="respiratory" post="tract, gastrointestinal tract, and conjunctiva Note: Data from these"/>
 <result pre="tears may also occur even years following the resolution of" exact="acute" post="ocular infection. T cells in tonsillar and adenoid lymphoid"/>
 <result pre="may also occur even years following the resolution of acute" exact="ocular" post="infection. T cells in tonsillar and adenoid lymphoid tissue"/>
 <result pre="steroid therapy can suppress the production of cytokines including TNF-alpha," exact="type I" post="IFN, and type II IFN, as well as depleted"/>
 <result pre="the production of cytokines including TNF-alpha, type I IFN, and" exact="type II" post="IFN, as well as depleted T cells and NK"/>
 <result pre="of antiviral cytokines that play a major role in inhibiting" exact="viral" post="replication. Inhibition of the IFN response allows for expression"/>
 <result pre="which results in reactivation and replication of HAdV DNA in" exact="epithelial" post="cell associated with latently infected lymphoid tissue and consequential"/>
 <result pre="facilitate dissemination of adenovirus into the community since subclinical adenoviral" exact="infection" post="of tonsillar and adenoid lymphoid tissue serve as a"/>
 <result pre="adenovirus in the stool of patients with previous adenoviral GIT" exact="infection" post="can also occur.3,11 Kosulin et al suggested that latent"/>
 <result pre="can also occur.3,11 Kosulin et al suggested that latent HAdV" exact="infection" post="of the gut lymphoid cell could serve as a"/>
 <result pre="adenovirus in human mucosal T lymphocytes or lymphoid tissue following" exact="primary" post="adenoviral infection.17 The stimulation of these adenovirus containing mucosal"/>
 <result pre="latent HAdV with consequential leakage of reactivated viruses into intestinal" exact="epithelial" post="cells, where adenoviruses undergo replication and subsequent shedding in"/>
 <result pre="shedding in stool.11,17,19-21 This is indicative of persistent subclinical HAdV" exact="infection" post="of the gut-associated lymphoid tissue.20 Immunocompetent individuals are likely"/>
 <result pre="also more likely to have reactivation of HAdV with productive" exact="infection" post="of intestinal epithelial cells and consequential extensive viral dissemination"/>
 <result pre="to have reactivation of HAdV with productive infection of intestinal" exact="epithelial" post="cells and consequential extensive viral dissemination in the community."/>
 <result pre="with productive infection of intestinal epithelial cells and consequential extensive" exact="viral" post="dissemination in the community. As such, in the immunocompromised"/>
 <result pre="an essential cause of HAdV dissemination.18 These resultant, latent adenoviral" exact="infections" post="are considered a significant challenge in managing and containing"/>
 <result pre="matter.18 Another significant challenge in managing adenoviral infections, particularly in" exact="Group D" post="HAdV, is the propensity for this group to cause"/>
 <result pre="to cause oculogenital infection. Several published cases have demonstrated that" exact="Group D" post="HAdV can be associated with concurrent urethritis and conjunctivitis.22â€“26"/>
 <result pre="demonstrated that Group D HAdV can be associated with concurrent" exact="urethritis" post="and conjunctivitis.22â€“26 HAdV 19 and 37 specifically have been"/>
 <result pre="young adults with EKC, indicating the possibility of sexual transmission.25,26" exact="Group D" post="HAdV type 37, for example, has been isolated from"/>
 <result pre="EKC, indicating the possibility of sexual transmission.25,26 Group D HAdV" exact="type 37," post="for example, has been isolated from sexually active men"/>
 <result pre="et al discussed eight cases of individuals presenting with concurrent" exact="conjunctivitis" post="and adenoviral urethritis.23 Avolio et al also presented a"/>
 <result pre="a case of two male patients with HAdV D37 associated" exact="urethritis" post="and conjunctivitis, in which one of the spouses contracted"/>
 <result pre="and conjunctivitis, in which one of the spouses contracted adenoviral" exact="conjunctivitis" post="via oculogenital contact. These cases highlight the importance of"/>
 <result pre="Children are to be encouraged to stay home during the" exact="infectious" post="phase to limit the spread of disease. Contact with"/>
 <result pre="also an option, though many times this method is of" exact="limited" post="use due to cost.28,29 Because of these unique viral"/>
 <result pre="of limited use due to cost.28,29 Because of these unique" exact="viral" post="characteristics, ubiquity of HAdV, and its potential for epidemic,"/>
 <result pre="oxidation of pathogen nucleotides, amino acids, and proteins, damaging vital" exact="bacterial" post="cellular mechanisms.32 Additionally, in vitro investigation indicates that PVI"/>
 <result pre="indicates that PVI impedes the hostâ€™s inflammatory response to a" exact="viral" post="pathogen by affecting both host and pathogen parameters.33 This"/>
 <result pre="(such as Î±-hemolysin, phospholipase C, and lipase) and suppression of" exact="bacterial" post="enzymes (such as elastase and ÃŸ-glucuronidase).32 Host factors involve"/>
 <result pre="dependent.35,36 PVI has been shown to demonstrate virucidal reductions for" exact="ocular" post="HAdV types 3, 4, 5, 7, and 8 at"/>
 <result pre="off-label.32 The theory behind in-office PVI irrigation is to reduce" exact="viral" post="load on the ocular surface and to decrease viral"/>
 <result pre="in-office PVI irrigation is to reduce viral load on the" exact="ocular" post="surface and to decrease viral shedding. A commonly implemented"/>
 <result pre="reduce viral load on the ocular surface and to decrease" exact="viral" post="shedding. A commonly implemented protocol in clinical practice involves"/>
 <result pre="swabbing of the eyelid margins), followed by lavage of the" exact="ocular" post="surface with sterile saline irrigation solution (Figure 1). Finally,"/>
 <result pre="drop is instilled. Anecdotally, patients may report exasperation of their" exact="conjunctivitis" post="symptoms for 12â€“24 hrs after this procedure; however, the"/>
 <result pre="for saline rinse. Interestingly, Cheung et al have indicated that" exact="multiple types" post="of adenovirus can be involved in a single outbreak"/>
 <result pre="outbreak and as PVI has proven viricidal activity in multiple" exact="ocular" post="types of HAdV, it would be sensible to consider"/>
 <result pre="sensible to consider PVI irrigation to decrease colonization of the" exact="ocular" post="surface in this disease picture.37 The most powerful tool"/>
 <result pre="irrigation to decrease colonization of the ocular surface in this" exact="disease" post="picture.37 The most powerful tool in limiting the severity"/>
 <result pre="The most powerful tool in limiting the severity of adenoviral" exact="conjunctivitis" post="outbreaks includes reduction of viral shedding and limiting contamination"/>
 <result pre="limiting the severity of adenoviral conjunctivitis outbreaks includes reduction of" exact="viral" post="shedding and limiting contamination of objects, workspaces, and surfaces"/>
 <result pre="of objects, workspaces, and surfaces in public places to avoid" exact="horizontal" post="transmission, as mentioned previously in this manuscript.38 Gargling or"/>
 <result pre="postulated as an effective measure in disrupting the transmission of" exact="respiratory" post="viral spread.39 Hence, PVI irrigation can be a powerful"/>
 <result pre="as an effective measure in disrupting the transmission of respiratory" exact="viral" post="spread.39 Hence, PVI irrigation can be a powerful tool"/>
 <result pre="of 1.25% PVI ophthalmic solution in the treatment of pediatric" exact="conjunctivitis" post="displayed efficacy in treatment of bacterial, chlamydial, and viral"/>
 <result pre="pediatric conjunctivitis displayed efficacy in treatment of bacterial, chlamydial, and" exact="viral" post="conjunctivitis.40 Interestingly, a clinical trial looking at 0.5% PVI"/>
 <result pre="pH 4.2 for enhanced tolerability) for the treatment of adenoviral" exact="keratoconjunctivitis" post="found faster recovery from disease at two weeks, with"/>
 <result pre="for the treatment of adenoviral keratoconjunctivitis found faster recovery from" exact="disease" post="at two weeks, with three drops administered thrice daily.34"/>
 <result pre="three drops administered thrice daily.34 Antiviral Therapy Antiviral activity against" exact="systemic" post="HAdV infections has been thoroughly studied and paved the"/>
 <result pre="administered thrice daily.34 Antiviral Therapy Antiviral activity against systemic HAdV" exact="infections" post="has been thoroughly studied and paved the way for"/>
 <result pre="for its more focused evaluation for the treatment of the" exact="ocular" post="manifestations of this virus. Besides the aforementioned forms of"/>
 <result pre="Besides the aforementioned forms of keratoconjunctivitis, HAdV may also cause" exact="upper" post="and lower respiratory tract disease, hemorrhagic cystitis, and gastroenteritis"/>
 <result pre="aforementioned forms of keratoconjunctivitis, HAdV may also cause upper and" exact="lower" post="respiratory tract disease, hemorrhagic cystitis, and gastroenteritis due to"/>
 <result pre="forms of keratoconjunctivitis, HAdV may also cause upper and lower" exact="respiratory" post="tract disease, hemorrhagic cystitis, and gastroenteritis due to its"/>
 <result pre="HAdV may also cause upper and lower respiratory tract disease," exact="hemorrhagic cystitis," post="and gastroenteritis due to its propensity to infect mucosal"/>
 <result pre="cause upper and lower respiratory tract disease, hemorrhagic cystitis, and" exact="gastroenteritis" post="due to its propensity to infect mucosal epithelium.3,41,42 Respiratory"/>
 <result pre="and gastroenteritis due to its propensity to infect mucosal epithelium.3,41,42" exact="Respiratory" post="infection is typically mild and self-limiting in immunocompetent individuals,"/>
 <result pre="gastroenteritis due to its propensity to infect mucosal epithelium.3,41,42 Respiratory" exact="infection" post="is typically mild and self-limiting in immunocompetent individuals, but"/>
 <result pre="and self-limiting in immunocompetent individuals, but in rare cases, severe" exact="respiratory" post="infection and pneumonia may result in acute respiratory distress"/>
 <result pre="self-limiting in immunocompetent individuals, but in rare cases, severe respiratory" exact="infection" post="and pneumonia may result in acute respiratory distress syndrome"/>
 <result pre="immunocompetent individuals, but in rare cases, severe respiratory infection and" exact="pneumonia" post="may result in acute respiratory distress syndrome (ARDS). Additionally,"/>
 <result pre="rare cases, severe respiratory infection and pneumonia may result in" exact="acute respiratory distress syndrome" post="(ARDS). Additionally, in immunocompromised patients undergoing hematopoietic stem cell"/>
 <result pre="cases, severe respiratory infection and pneumonia may result in acute" exact="respiratory" post="distress syndrome (ARDS). Additionally, in immunocompromised patients undergoing hematopoietic"/>
 <result pre="respiratory infection and pneumonia may result in acute respiratory distress" exact="syndrome" post="(ARDS). Additionally, in immunocompromised patients undergoing hematopoietic stem cell"/>
 <result pre="patients undergoing hematopoietic stem cell or solid organ transplantation, disseminated" exact="infections" post="can be life-threatening, particularly in the pediatric population.3 Despite"/>
 <result pre="2Ê¹-deoxyguanosine, has been proven effective in the inhibition of the" exact="herpes" post="family of viruses, specifically herpes simplex types 1 and"/>
 <result pre="in the inhibition of the herpes family of viruses, specifically" exact="herpes" post="simplex types 1 and 2, varicella-zoster virus, cytomegalovirus, and"/>
 <result pre="inhibition of the herpes family of viruses, specifically herpes simplex" exact="types 1 and 2," post="varicella-zoster virus, cytomegalovirus, and Epstein-Barr. In a series of"/>
 <result pre="hamsters infected with HAdV 5, GCV was able to suppress" exact="viral" post="replication in the liver, a method that may involve"/>
 <result pre="polymerase. It was proposed that GCV inhibited the advancement of" exact="viral infection" post="into the late phase. Systemically, GCV was able to"/>
 <result pre="It was proposed that GCV inhibited the advancement of viral" exact="infection" post="into the late phase. Systemically, GCV was able to"/>
 <result pre="Systemically, GCV was able to mitigate the effects of HAdV" exact="infection" post="in these hamsters, decreasing the rate of mortality. This"/>
 <result pre="led to the investigation of GCV in the treatment of" exact="ocular" post="infections of HAdV.43,44 The ophthalmic gel form (ganciclovir 0.15%,"/>
 <result pre="to the investigation of GCV in the treatment of ocular" exact="infections" post="of HAdV.43,44 The ophthalmic gel form (ganciclovir 0.15%, VirganÂ®;"/>
 <result pre="has been the standard of care for the treatment of" exact="acute" post="ocular herpetic keratitis, yet it has not been standardized"/>
 <result pre="been the standard of care for the treatment of acute" exact="ocular" post="herpetic keratitis, yet it has not been standardized in"/>
 <result pre="the standard of care for the treatment of acute ocular" exact="herpetic keratitis," post="yet it has not been standardized in the management"/>
 <result pre="use, GCV inhibits the replication of HAdV that leads to" exact="ocular" post="infection. Several clinical trials have reported its efficacy.43â€“46 In"/>
 <result pre="therapeutic effect of GCV in that the incidence of HAdV" exact="infections" post="was significantly reduced in stem cell-transplant patients treated with"/>
 <result pre="this study, interferon was administered with the purpose of inhibiting" exact="viral" post="replication, while GCV was used for its antiviral properties."/>
 <result pre="for its antiviral properties. To improve efficacy and limit potential" exact="ocular" post="side effects, such as inflammation, congestion, and edema, tobramycin-dexamethasone"/>
 <result pre="a 6-week treatment period, with low risk of side effects" exact="limited" post="to transient corneal epithelial defects and elevated intraocular pressure."/>
 <result pre="treatment period, with low risk of side effects limited to" exact="transient" post="corneal epithelial defects and elevated intraocular pressure. While EKC"/>
 <result pre="with low risk of side effects limited to transient corneal" exact="epithelial" post="defects and elevated intraocular pressure. While EKC is often"/>
 <result pre="antiviral activity against HAdV in vitro. However, many of these" exact="systemic" post="antiviral therapies lead to the risk of significant side"/>
 <result pre="diphosphate form and binds to the HAdV DNA polymerase, causing" exact="viral" post="DNA chain termination and viral inhibition.13,44 Intravenous cidofovir is"/>
 <result pre="the HAdV DNA polymerase, causing viral DNA chain termination and" exact="viral" post="inhibition.13,44 Intravenous cidofovir is often used in transplant clinics"/>
 <result pre="used systemically, leads to nephrotoxicity.44,46 Locally, CDV may also cause" exact="ocular" post="toxicity around the skin of eyelids and conjunctiva.46 Similarly,"/>
 <result pre="of eyelids and conjunctiva.46 Similarly, ribavirin also results in poor" exact="systemic" post="side effects and safety profile, associated with extravascular hemolysis,"/>
 <result pre="effects and safety profile, associated with extravascular hemolysis, anemia, and" exact="bone marrow suppression." post="Due to these discoveries, it is necessary to determine"/>
 <result pre="20 consecutive days; the results displayed significant effectivity against HAdV" exact="type 5" post="when compared to the placebo group, reducing both viral"/>
 <result pre="type 5 when compared to the placebo group, reducing both" exact="viral" post="shedding and the severity of sub-epithelial infiltrates. This study"/>
 <result pre="promise in the future of cidofovir for the treatment of" exact="ocular" post="HAdV infections in the future.48 Additionally, early systemic administration"/>
 <result pre="the future of cidofovir for the treatment of ocular HAdV" exact="infections" post="in the future.48 Additionally, early systemic administration of CDV"/>
 <result pre="treatment of ocular HAdV infections in the future.48 Additionally, early" exact="systemic" post="administration of CDV in immunocompetent patients with HAdV pneumonia"/>
 <result pre="early systemic administration of CDV in immunocompetent patients with HAdV" exact="pneumonia" post="was an effective treatment strategy.42 Due to the positive"/>
 <result pre="prophylaxis with 1% and 0.5% concentrations of CDV significantly reduced" exact="viral" post="replication of HAdV type 5 in animal models, giving"/>
 <result pre="0.5% concentrations of CDV significantly reduced viral replication of HAdV" exact="type 5" post="in animal models, giving promise to the use of"/>
 <result pre="models, several studies discussed the significant side effects to the" exact="ocular" post="surface, which is a potential limitation for therapeutic use."/>
 <result pre="in uninfected animals, determining that there was consistent clinically significant" exact="ocular" post="toxicity at a total dose exceeding 15mg over 10"/>
 <result pre="that there was consistent clinically significant ocular toxicity at a" exact="total" post="dose exceeding 15mg over 10 days.50 Significant eyelid redness"/>
 <result pre="studies as well as nasolacrimal blockage and lacrimation.50,51 Even at" exact="lower" post="and presumably ineffective dosages, 3.5 mg of cidofovir continued"/>
 <result pre="presumably ineffective dosages, 3.5 mg of cidofovir continued exhibit significant" exact="ocular" post="surface toxicity in vivo.52 Resistance to CDV is likely"/>
 <result pre="of cidofovir continued exhibit significant ocular surface toxicity in vivo.52" exact="Resistance" post="to CDV is likely due to changes in amino"/>
 <result pre="resistance poses a significant challenge to the management of adenoviral" exact="keratoconjunctivitis" post="in the clinical setting.53 Romanowski et al were able"/>
 <result pre="setting.53 Romanowski et al were able to demonstrate that HAdV" exact="type 5" post="that are resistant to topical CVD therapy are less"/>
 <result pre="likely to constitute a significant challenge in management of adenoviral" exact="keratoconjunctivitis" post="in immunocompetent patients. Drug-resistant viruses usually pose a minimal"/>
 <result pre="CDV-resistant HAdV can retain their ability to replicate in permissive" exact="ocular" post="epithelial cells.54 Another major challenge to the use of"/>
 <result pre="HAdV can retain their ability to replicate in permissive ocular" exact="epithelial" post="cells.54 Another major challenge to the use of CDV"/>
 <result pre="major challenge to the use of CDV for treating adenoviral" exact="keratoconjunctivitis" post="is its propensity to lead to toxicity, which manifests"/>
 <result pre="its propensity to lead to toxicity, which manifests as persistent" exact="epiphora" post="from lacrimal canalicular blockade.53 As such, despite its potential,"/>
 <result pre="to lead to toxicity, which manifests as persistent epiphora from" exact="lacrimal" post="canalicular blockade.53 As such, despite its potential, its high"/>
 <result pre="reported successful use of BCV in the treatment of adenoviral" exact="infection" post="in a patient with primary immunodeficiency whereas Florescu et"/>
 <result pre="in the treatment of adenoviral infection in a patient with" exact="primary" post="immunodeficiency whereas Florescu et al demonstrated that it was"/>
 <result pre="the treatment of adenoviral infection in a patient with primary" exact="immunodeficiency" post="whereas Florescu et al demonstrated that it was clinically"/>
 <result pre="al demonstrated that it was clinically beneficial in treating adenoviral" exact="infection" post="in immunocompromised individuals who were at risk of disseminated"/>
 <result pre="as well as its potential for the treatment of adenoviral" exact="ocular" post="infections. Clinical development of this drug is ongoing, as"/>
 <result pre="be the most favorable in terms of antiviral activity and" exact="limited" post="systemic or local side effects.46 Immunoglobulin (Ig)-Based Therapy In"/>
 <result pre="the most favorable in terms of antiviral activity and limited" exact="systemic" post="or local side effects.46 Immunoglobulin (Ig)-Based Therapy In 2001,"/>
 <result pre="the antibodies' ability to target adenoviral capsid proteins, subsequently inhibiting" exact="infection" post="by the virus.58 Topically, immunoglobulin (Ig) may offer the"/>
 <result pre="virus.58 Topically, immunoglobulin (Ig) may offer the same effect on" exact="ocular" post="tissue and prevent transmission and replication of the virus,"/>
 <result pre="to block DNA replication, Ig neutralizes the virus on the" exact="ocular" post="surface. In comparison to cidofovir and saline titers, Ig"/>
 <result pre="cidofovir and saline titers, Ig was more effective during the" exact="acute" post="phase of the infection.59 It worked to aid in"/>
 <result pre="in this study, cidofovir demonstrated a significantly shorter duration of" exact="viral" post="shedding. This is likely due to the mechanism of"/>
 <result pre="promising results in the future of topical Ig use on" exact="ocular" post="HAdV infections. The limitation lies in product consistency as"/>
 <result pre="from serum pooled by various donors, though anti-adenoviral efficacy appears" exact="stable" post="over different lots.59,60 Topical Anti-Inflammatory Therapy Corneal involvement in"/>
 <result pre="anti-adenoviral efficacy appears stable over different lots.59,60 Topical Anti-Inflammatory Therapy" exact="Corneal" post="involvement in EKC occurs in approximately 80% of cases,"/>
 <result pre="of cases, varying in presentation as a superficial punctate keratitis," exact="focal" post="epithelial punctate keratitis, subepithelial infiltrate (SEI) formation, and reduced"/>
 <result pre="cases, varying in presentation as a superficial punctate keratitis, focal" exact="epithelial" post="punctate keratitis, subepithelial infiltrate (SEI) formation, and reduced corneal"/>
 <result pre="often manifest anywhere from one to three weeks following the" exact="acute" post="phase of the infection. Histologically they are comprised of"/>
 <result pre="to years following resolution of the conjunctivitis, leading to subjective" exact="visual" post="disturbances, such as decreased vision, photophobia, halos, and the"/>
 <result pre="such as decreased vision, photophobia, halos, and the development of" exact="irregular astigmatism." post="Due to their chronicity and visual impact, treatments including"/>
 <result pre="the development of irregular astigmatism. Due to their chronicity and" exact="visual" post="impact, treatments including anti-inflammatory and immunosuppressive agents have been"/>
 <result pre="SEIs, though they often end up resolving without scarring or" exact="corneal neovascularization" post="formation.2,12,62 Research demonstrates that mild corticosteroid treatment administered topically"/>
 <result pre="can significantly improve EKC symptoms and, if used in the" exact="short" post="term, acute phase of the disease, does not lead"/>
 <result pre="improve EKC symptoms and, if used in the short term," exact="acute" post="phase of the disease, does not lead to significant"/>
 <result pre="acute phase of the disease, does not lead to significant" exact="ocular" post="side effects. There is also additional benefit in the"/>
 <result pre="additional benefit in the use of topical corticosteroids once the" exact="acute" post="phase of the infection resolves, for the remaining, persistent"/>
 <result pre="use of topical corticosteroids once the acute phase of the" exact="infection" post="resolves, for the remaining, persistent SEIs.2,63 While chronic corticosteroid"/>
 <result pre="of the infection resolves, for the remaining, persistent SEIs.2,63 While" exact="chronic" post="corticosteroid treatment has been proven to reduce these findings,"/>
 <result pre="treatment is the risk of complications of long-term use, including" exact="glaucoma" post="and cataract formation.64â€“69 Additionally, corticosteroid treatment of SEIs can"/>
 <result pre="is the risk of complications of long-term use, including glaucoma" exact="and cataract" post="formation.64â€“69 Additionally, corticosteroid treatment of SEIs can result in"/>
 <result pre="the risk of complications of long-term use, including glaucoma and" exact="cataract" post="formation.64â€“69 Additionally, corticosteroid treatment of SEIs can result in"/>
 <result pre="rate and consequential, unsuccessful drug tapering.70 If discontinued abruptly, these" exact="viral" post="antigens continue to attract lymphocytes, causing persistence of SEIs.62,66"/>
 <result pre="important to note that short-term treatment with topical steroids of" exact="limited" post="potency may also delay viral clearance.72 Nonsteroidal anti-inflammatory drugs"/>
 <result pre="treatment with topical steroids of limited potency may also delay" exact="viral" post="clearance.72 Nonsteroidal anti-inflammatory drugs (NSAIDs) are another alternative to"/>
 <result pre="alternative to corticosteroids, in that they are approved for topical," exact="ocular" post="use and exhibit anti-inflammatory effects without the substantial risk"/>
 <result pre="use and exhibit anti-inflammatory effects without the substantial risk of" exact="glaucoma" post="and cataract effect seen with steroid use. These agents"/>
 <result pre="and exhibit anti-inflammatory effects without the substantial risk of glaucoma" exact="and cataract" post="effect seen with steroid use. These agents work on"/>
 <result pre="exhibit anti-inflammatory effects without the substantial risk of glaucoma and" exact="cataract" post="effect seen with steroid use. These agents work on"/>
 <result pre="the formation of prostaglandins, thromboxane, and prostacyclin. With specificity to" exact="ocular" post="uses, they have been shown to be effective in"/>
 <result pre="they have been shown to be effective in cases of" exact="allergic conjunctivitis," post="alkali burns, herpetic uveitis, ocular trauma, and pre/post-operative cataract"/>
 <result pre="effective in cases of allergic conjunctivitis, alkali burns, herpetic uveitis," exact="ocular" post="trauma, and pre/post-operative cataract and refractive surgeries.73â€“76 Gordon et"/>
 <result pre="allergic conjunctivitis, alkali burns, herpetic uveitis, ocular trauma, and pre/post-operative" exact="cataract" post="and refractive surgeries.73â€“76 Gordon et al were the first"/>
 <result pre="and late phases of infection, the effect of NSAIDs on" exact="viral" post="titers did not differ from control groups, nor did"/>
 <result pre="from control groups, nor did it affect the duration of" exact="viral" post="shedding. In contrast, prednisolone treatment was shown to prolong"/>
 <result pre="viral shedding. In contrast, prednisolone treatment was shown to prolong" exact="viral" post="shedding.73 As it pertained to sub-epithelial infiltrates, treatment with"/>
 <result pre="substantia propria of mucous membranes; both are common in adenoviral" exact="keratoconjunctivitis" post="and may hemorrhage upon removal.1 Histopathological studies indicate the"/>
 <result pre="Because pseudomembrane formation can present in severe cases of adenoviral" exact="keratoconjunctivitis" post="in the setting of an intense inflammatory response (Figure"/>
 <result pre="avoid transplant rejection by tempering the hostâ€™s own immune response.77" exact="Ocular" post="use in HAdV keratoconjunctivitis should be considered when there"/>
 <result pre="tempering the hostâ€™s own immune response.77 Ocular use in HAdV" exact="keratoconjunctivitis" post="should be considered when there is a need to"/>
 <result pre="concentrations) is an alternative option which, if used in the" exact="acute" post="phase of adenoviral keratoconjunctivitis, is successful in both reducing"/>
 <result pre="the risk of developing corneal findings as well as the" exact="chronic" post="treatment of persistent SEIs, with most cases resolving over"/>
 <result pre="day or once every other day, in treatment of SEIs" exact="secondary" post="to adenoviral epidemic keratoconjunctivitis in cases persisting for more"/>
 <result pre="other day, in treatment of SEIs secondary to adenoviral epidemic" exact="keratoconjunctivitis" post="in cases persisting for more than three months. Patients"/>
 <result pre="SEIs while the remaining 18.2% had decreased in number. No" exact="systemic" post="or ocular side effects were observed. Few cases (11.12%)"/>
 <result pre="the remaining 18.2% had decreased in number. No systemic or" exact="ocular" post="side effects were observed. Few cases (11.12%) in this"/>
 <result pre="the inhibition of T cell proliferation and activation, thereby reducing" exact="ocular" post="surface inflammation.77 It has been shown to be efficacious"/>
 <result pre="inflammation.77 It has been shown to be efficacious in various" exact="ocular" post="diseases, such as vernal keratoconjunctivitis, ulcerative keratitis, Thygeson superficial"/>
 <result pre="in various ocular diseases, such as vernal keratoconjunctivitis, ulcerative keratitis," exact="Thygeson superficial punctate keratitis," post="herpes stromal keratitis, dry eye disease, superior limbic keratoconjunctivitis,"/>
 <result pre="such as vernal keratoconjunctivitis, ulcerative keratitis, Thygeson superficial punctate keratitis," exact="herpes" post="stromal keratitis, dry eye disease, superior limbic keratoconjunctivitis, and"/>
 <result pre="ulcerative keratitis, Thygeson superficial punctate keratitis, herpes stromal keratitis, dry" exact="eye disease," post="superior limbic keratoconjunctivitis, and many others.69,79-81 Asena et al"/>
 <result pre="many others.69,79-81 Asena et al also evaluated treatment options for" exact="acute" post="adenoviral keratoconjunctivitis using either topical 1% prednisolone acetate in"/>
 <result pre="Asena et al also evaluated treatment options for acute adenoviral" exact="keratoconjunctivitis" post="using either topical 1% prednisolone acetate in conjunction with"/>
 <result pre="tacrolimus 0.03% has ophthalmic uses, mainly in the treatment of" exact="giant papillary conjunctivitis" post="and vernal keratoconjunctivitis. With regards to its effect on"/>
 <result pre="0.03% has ophthalmic uses, mainly in the treatment of giant" exact="papillary conjunctivitis" post="and vernal keratoconjunctivitis. With regards to its effect on"/>
 <result pre="has ophthalmic uses, mainly in the treatment of giant papillary" exact="conjunctivitis" post="and vernal keratoconjunctivitis. With regards to its effect on"/>
 <result pre="resolution of clinical signs and symptoms but also offered a" exact="lower" post="recurrence rate and no significant rise in IOP as"/>
 <result pre="patients to fight infection. HAdV-specific T cells are present in" exact="peripheral" post="blood of healthy individuals in low frequencies; as a"/>
 <result pre="HAdV infection. HAdV-specific T cells play a significant role in" exact="viral" post="clearance, and as such, adoptive transfer of HAdV-specific T"/>
 <result pre="suppress HAdV. Historically, these drugs have been used to treat" exact="heart" post="failure for over 200 years. More recently, they have"/>
 <result pre="200 years. More recently, they have also shown efficacy in" exact="cancer" post="treatments, in that treated patients demonstrated a lesser chance"/>
 <result pre="of digoxin, the antiviral uses of cardiotonic steroids would be" exact="short" post="term, negating the associated systemic complications. As such, these"/>
 <result pre="of cardiotonic steroids would be short term, negating the associated" exact="systemic" post="complications. As such, these drugs seem to be efficacious"/>
 <result pre="steroids as an antiviral agent for short-term treatment of adenoviral" exact="keratoconjunctivitis" post="as well as a prophylactic for use in individuals"/>
 <result pre="synthetic steroid drug, possesses anti-adenoviral properties via its interference with" exact="viral" post="entry into the nucleus. As such, it could be"/>
 <result pre="to employ the antiseptic properties of PVI in conjunction with" exact="symptomatic" post="relief of inflammation, with the added benefit of reducing"/>
 <result pre="study of nine eyes utilizing Rapid Pathogen Screening Adeno Detector-positive" exact="acute" post="viral conjunctivitis.91 The pilot study included both clinical (conjunctival"/>
 <result pre="of nine eyes utilizing Rapid Pathogen Screening Adeno Detector-positive acute" exact="viral" post="conjunctivitis.91 The pilot study included both clinical (conjunctival injection"/>
 <result pre="(reduction of quantitative polymerase chain reaction titers and eradication of" exact="infectious" post="virus as determined by cell culture with confirmatory immunofluorescence)"/>
 <result pre="also been shown to improve clinical scores for scleral inflammation," exact="ocular" post="neovascularization, eyelid inflammation, friability of vasculature, inflammatory discharge, and"/>
 <result pre="shown to improve clinical scores for scleral inflammation, ocular neovascularization," exact="eyelid inflammation," post="friability of vasculature, inflammatory discharge, and epiphora as compared"/>
 <result pre="ocular neovascularization, eyelid inflammation, friability of vasculature, inflammatory discharge, and" exact="epiphora" post="as compared to treatment with 0.5% cidofovir, tobramycin/dexamethasone ophthalmic"/>
 <result pre="rabbit models.52 Moreover, PVI/dexamethasone combination has proven effective in reducing" exact="viral" post="titers and delaying viral shedding.52 When comparing PVI/dexamethasone combination"/>
 <result pre="combination has proven effective in reducing viral titers and delaying" exact="viral" post="shedding.52 When comparing PVI/dexamethasone combination treatment with that of"/>
 <result pre="that sole topical corticosteroid therapy has the risk of increased" exact="viral" post="replication and prolonged shedding, further delaying the resolution of"/>
 <result pre="often associated with topical corticosteroid use. Reported side effects were" exact="limited" post="to increased stinging upon instillation when compared to treatment"/>
 <result pre="fibrotic remodeling of the conjunctiva or sustained corneal scarring with" exact="visual" post="consequence. Membranes that develop on the mucosal surface can"/>
 <result pre="true membranes, with the latter being clinically distinguished by induced" exact="bleeding" post="upon denuding.1 Persistence of pseudomembrane can lead to subepithelial"/>
 <result pre="be present in severe cases, with membranes that can precipitate" exact="corneal perforation" post="and necessitate treatment.95 For patients with chronic adenoviral corneal"/>
 <result pre="can precipitate corneal perforation and necessitate treatment.95 For patients with" exact="chronic" post="adenoviral corneal opacification following resolution of acute infection, phototherapeutic"/>
 <result pre="For patients with chronic adenoviral corneal opacification following resolution of" exact="acute" post="infection, phototherapeutic keratectomy (PTK) can be an alternative option"/>
 <result pre="be an alternative option to other corneal surgeries or transplants." exact="Corneal" post="transparency can be compromised, or corneal irregularity may result"/>
 <result pre="corrected vision, and contrast sensitivity.96 Furthermore, a decrease in coma," exact="secondary" post="astigmatism, and total higher-order aberrations have been noted after"/>
 <result pre="contrast sensitivity.96 Furthermore, a decrease in coma, secondary astigmatism, and" exact="total" post="higher-order aberrations have been noted after PTK for SEIs"/>
 <result pre="adenoviral keratoconjunctivitis.97 Conclusion and Future Perspectives Though many consider adenoviral" exact="conjunctivitis" post="a disease of self-limitation, the economic burden on affected"/>
 <result pre="Conclusion and Future Perspectives Though many consider adenoviral conjunctivitis a" exact="disease" post="of self-limitation, the economic burden on affected individuals, high"/>
 <result pre="burden on affected individuals, high contagion risk, and potential long-term" exact="visual" post="complications require a treatment protocol. Studies have indicated that"/>
 <result pre="infection. These individuals include children, elderly, immunocompromised individual, patients with" exact="acute" post="Graft versus Host disease, those on immunosuppressants, and so"/>
 <result pre="eye care providers use multiple pharmaceuticals off-label to manage HAdV" exact="ocular" post="infection. Finally, the propensity for latent HAdV to become"/>
 <result pre="as a topical treatment.95,99 CAP is of use in dermatological" exact="disease" post="and chronic wounds and has demonstrated adenoviral type-dependent antiviral"/>
 <result pre="topical treatment.95,99 CAP is of use in dermatological disease and" exact="chronic" post="wounds and has demonstrated adenoviral type-dependent antiviral effect that"/>
 <result pre="clinical trials were prematurely ended due to inability to meet" exact="primary" post="and secondary endpoints.101 These endpoints included clearing of bulbar"/>
 <result pre="were prematurely ended due to inability to meet primary and" exact="secondary" post="endpoints.101 These endpoints included clearing of bulbar conjunctiva, eradication"/>
 <result pre="meet primary and secondary endpoints.101 These endpoints included clearing of" exact="bulbar" post="conjunctiva, eradication of virus from tear film, fellow eye"/>
 <result pre="in concentrations higher than 0.1%; however, note the disadvantage of" exact="ocular" post="toxicity from the known disinfectant.103 Future considerations in the"/>
 <result pre="the known disinfectant.103 Future considerations in the management of adenoviral" exact="keratoconjunctivitis" post="should require consideration of antisepsis and mitigation of sequelae"/>
 <result pre="exact mechanisms that underlie the adaptive immune response in adenoviral" exact="infections" post="is prudent to the development of novel therapeutic sources."/>
 <result pre="lack of animal models that accurately mimic complexity of human" exact="ocular" post="anatomy while also illustrating proper replication and infection of"/>
 <result pre="of human ocular anatomy while also illustrating proper replication and" exact="infection" post="of human adenoviruses can prove decelerating for new discovery.95Table"/>
 <result pre="Effects PVI irrigation Off-label use for EKC; reduces risk of" exact="disease" post="transmission Dry eye symptoms, corneal epithelial damage/toxicity with repeated"/>
 <result pre="EKC; reduces risk of disease transmission Dry eye symptoms, corneal" exact="epithelial" post="damage/toxicity with repeated use. 104 Cidofovir Antiviral activity against"/>
 <result pre="for greater than one week associated with rare cases of" exact="lacrimal" post="canalicularblockade in rabbit models.107 Ganciclovir 3% ganciclovir reduced HAdV"/>
 <result pre="cause EKC.46 Ganciclovir ophthalmic gel treatment prevents complications in adenoviral" exact="ocular" post="infection. 109 Transient blur following instillation, eye irritation, punctate"/>
 <result pre="ophthalmic gel treatment prevents complications in adenoviral ocular infection. 109" exact="Transient" post="blur following instillation, eye irritation, punctate keratitis, conjunctival hyperemia.108"/>
 <result pre="tract upset, asymptomatic and elevated levels of serum transaminases114 diarrhea," exact="acute" post="graft versus host disease, abdominal pain, nausea/vomiting, decreased appetite,"/>
 <result pre="acute graft versus host disease, abdominal pain, nausea/vomiting, decreased appetite," exact="peripheral" post="edema, hyperglycemia, hypokalemia, rash, fatigue, fever.115 Topical corticosteroids Relief"/>
 <result pre="Topical corticosteroids Relief of EKC symptoms and Persistent adenoviral SEIs.2,63" exact="Glaucoma" post="and cataracts.116 Topical cyclosporine Effective against persistent adenoviral SEIs.66,69,117â€“119"/>
 <result pre="Glaucoma and cataracts.116 Topical cyclosporine Effective against persistent adenoviral SEIs.66,69,117â€“119" exact="Transient" post="or long-lasting burning sensation;120 ocular pain/irritation, redness; eyelid swelling"/>
 <result pre="Effective against persistent adenoviral SEIs.66,69,117â€“119 Transient or long-lasting burning sensation;120" exact="ocular" post="pain/irritation, redness; eyelid swelling in Steven Johnsons patients.121 Topical"/>
 <result pre="well as a safe and effective treatment of adenoviral SEIs.87,122,123" exact="Transient" post="burning sensation.124 Table 3 Challenges and Solutions in the"/>
 <result pre="Table 3 Challenges and Solutions in the Management of Adenoviral" exact="Keratoconjunctivitis" post="Challenges Potential Solutions High likelihood of transmission and epidemic"/>
 <result pre="in the host Prevention of spread, treatment of immunocompromised individuals" exact="Group D" post="HAdV can cause oculogenital infection Appropriate testing for HAdV"/>
 <result pre="treatment of immunocompromised individuals Group D HAdV can cause oculogenital" exact="infection" post="Appropriate testing for HAdV subtype from urethra and conjunctiva"/>
 <result pre="therapy Side effects of long-term corticosteroid use (ie, elevated IOP" exact="and cataract" post="formation) Immunotherapy such as topical cyclosporine or tacrolimus Corticosteroids"/>
 <result pre="Side effects of long-term corticosteroid use (ie, elevated IOP and" exact="cataract" post="formation) Immunotherapy such as topical cyclosporine or tacrolimus Corticosteroids"/>
 <result pre="formation) Immunotherapy such as topical cyclosporine or tacrolimus Corticosteroids prolonging" exact="viral" post="shedding Combination PVI/dexamethasone ophthalmic solution Conjunctival or corneal scarring"/>
 <result pre="CookJL. Human adenovirus infections: update and consideration of mechanisms of" exact="viral" post="persistence. Curr Opin Infect Dis. 2018;31(3):251â€“256. doi:10.1097/QCO.000000000000045129601326 4.Iacobelli-MartinezM, NemerowGR."/>
 <result pre="doi:10.1007/82_2010_1620376613 10.GordonYJ, Araullo-CruzTP, JohnsonYF, RomanowskiEG, KinchingtonPR. Isolation of human adenovirus" exact="type 5" post="variants resistant to the antiviral cidofovir. Invest Ophthalmol Vis"/>
 <result pre="to the antiviral cidofovir. Invest Ophthalmol Vis Sci. 1996;37(13):2774â€“2778.8977495 11.KosulinK." exact="Intestinal" post="HAdV infection: tissue specificity, persistence, and implications for antiviral"/>
 <result pre="implications for antiviral therapy. Viruses. 2019;11:9. doi:10.3390/v11090804 12.GhebremedhinB. Human adenovirus:" exact="viral" post="pathogen with increasing importance. Eur J Microbiol Immunol (Bp)."/>
 <result pre="importance. Eur J Microbiol Immunol (Bp). 2014;4(1):26â€“33. doi:10.1556/EuJMI.4.2014.1.224678403 13.LionT. Adenovirus" exact="infections" post="in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441â€“462."/>
 <result pre="Dis J. 2010;29(8):746â€“750. doi:10.1097/INF.0b013e3181d743c820308936 15.FlammerJR, DobrovolnaJ, KennedyMA, et al. The" exact="type I" post="interferon signaling pathway is a target for glucocorticoid inhibition."/>
 <result pre="22.AvolioM, De RosaR, ModoloML, StanoP, CamporeseA. When should adenoviral non-gonococcal" exact="urethritis" post="be suspected? Two case reports. New Microbiol. 2014;37(1):109â€“112.24531179 23.LiddleOL,"/>
 <result pre="reports. New Microbiol. 2014;37(1):109â€“112.24531179 23.LiddleOL, SamuelMI, SudhanvaM, EllisJ, TaylorC. Adenovirus" exact="urethritis" post="and concurrent conjunctivitis: a case series and review of"/>
 <result pre="2015;91(2):87â€“90. doi:10.1136/sextrans-2014-05186825433050 24.SamaraweeraGR, GarciaK, DruceJ, et al. Characteristics of adenovirus" exact="urethritis" post="among heterosexual men and men who have sex with"/>
 <result pre="BaiY, YangH. Analysis on the treatment and prevention of epidemic" exact="conjunctivitis" post="in 108 cases. Pak J Pharm Sci. 2017;30(4(Suppl.)):1501â€“1503.29044005 28.BuehlerJW,"/>
 <result pre="Pak J Pharm Sci. 2017;30(4(Suppl.)):1501â€“1503.29044005 28.BuehlerJW, FintonRJ, GoodmanRA, et al." exact="Epidemic" post="keratoconjunctivitis: report of an outbreak in an ophthalmology practice"/>
 <result pre="KowalskiRP, RomanowskiEG. The in vitro evaluation of povidone-iodine against multiple" exact="ocular" post="adenoviral types. J Ocul Pharmacol Ther. 2019;35(2):132â€“136. doi:10.1089/jop.2018.012230589605 37.CheungD,"/>
 <result pre="types. J Ocul Pharmacol Ther. 2019;35(2):132â€“136. doi:10.1089/jop.2018.012230589605 37.CheungD, BremnerJ, ChanJT." exact="Epidemic" post="kerato-conjunctivitisâ€“do outbreaks have to be epidemic?Eye (Lond). 2003;17(3):356â€“363. doi:10.1038/sj.eye.670033012724699"/>
 <result pre="El-amirAN, MaddisonT, et al. Identification and control of nosocomial adenovirus" exact="keratoconjunctivitis" post="in an ophthalmic department. Br J Ophthalmol. 2009;93(1):18â€“20. doi:10.1136/bjo.2007.13011218697812"/>
 <result pre="and effective virucidal activity of povidone-iodine products against Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)."/>
 <result pre="effective virucidal activity of povidone-iodine products against Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA). Infect"/>
 <result pre="products against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified" exact="Vaccinia" post="Virus Ankara (MVA). Infect Dis Ther. 2015;4(4):491â€“501. doi:10.1007/s40121-015-0091-926416214 40.IsenbergSJ,"/>
 <result pre="ValentonM, et al. A controlled trial of povidone-iodine to treat" exact="infectious" post="conjunctivitis in children. Am J Ophthalmol. 2002;134(5):681â€“688. doi:10.1016/S0002-9394(02)01701-412429243 41.PhamTT,"/>
 <result pre="et al. A controlled trial of povidone-iodine to treat infectious" exact="conjunctivitis" post="in children. Am J Ophthalmol. 2002;134(5):681â€“688. doi:10.1016/S0002-9394(02)01701-412429243 41.PhamTT, BurchetteJLJr.,"/>
 <result pre="J Ophthalmol. 2002;134(5):681â€“688. doi:10.1016/S0002-9394(02)01701-412429243 41.PhamTT, BurchetteJLJr., HaleLP. Fatal disseminated adenovirus" exact="infections" post="in immunocompromised patients. Am J Clin Pathol. 2003;120(4):575â€“583. doi:10.1309/AWXDGNC5D70EN7YT14560569"/>
 <result pre="Pharmacother. 2015;16(14):2095â€“2099. doi:10.1517/14656566.2015.108397526330121 45.BrunoB, GooleyT, HackmanRC, DavisC, CoreyL, BoeckhM. Adenovirus" exact="infection" post="in hematopoietic stem cell transplantation: effect of ganciclovir and"/>
 <result pre="cell transplantation: effect of ganciclovir and impact on survival. Biol" exact="Blood" post="Marrow Transplant. 2003;9(5):341â€“352. doi:10.1016/S1083-8791(03)00102-212766884 46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects"/>
 <result pre="46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects of ganciclovir in types inducing" exact="keratoconjunctivitis" post="by quantitative polymerase chain reaction methods. Clin Ophthalmol. 2014;8:315â€“320."/>
 <result pre="Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed" exact="female" post="and male Syrian hamsters. Viruses. 2015;7(3):1409â€“1428. doi:10.3390/v703140925807051 48.de OliveiraCB,"/>
 <result pre="LaBreeL, McDonnellPJ, TrousdaleMD. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus" exact="type 5" post="infection in vitro and in a New Zealand rabbit"/>
 <result pre="TrousdaleMD. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5" exact="infection" post="in vitro and in a New Zealand rabbit ocular"/>
 <result pre="5 infection in vitro and in a New Zealand rabbit" exact="ocular" post="model. Antiviral Res. 1996;31(3):165â€“172. doi:10.1016/0166-3542(95)00962-08811201 49.RomanowskiEG, YatesKA, GordonYJ. Antiviral"/>
 <result pre="protects against challenge in the adenovirus type 5/New Zealand rabbit" exact="ocular" post="model. Antiviral Res. 2001;52(3):275â€“280. doi:10.1016/S0166-3542(01)00166-811675144 50.GordonYJ, RomanowskiEG, Araullo-CruzT. Topical"/>
 <result pre="Res. 2001;52(3):275â€“280. doi:10.1016/S0166-3542(01)00166-811675144 50.GordonYJ, RomanowskiEG, Araullo-CruzT. Topical HPMPC inhibits adenovirus" exact="type 5" post="in the New Zealand rabbit ocular replication model. Invest"/>
 <result pre="HPMPC inhibits adenovirus type 5 in the New Zealand rabbit" exact="ocular" post="replication model. Invest Ophthalmol Vis Sci. 1994;35(12):4135â€“4143.7960596 51.InoueH, SonodaKH,"/>
 <result pre="1994;35(12):4135â€“4143.7960596 51.InoueH, SonodaKH, IshikawaM, KadonosonoK, UchioE. Clinical evaluation of local" exact="ocular" post="toxicity in candidate anti-adenoviral agents in vivo. Ophthalmologica. 2009;223(4):233â€“238."/>
 <result pre="Araullo-CruzT, VergnesJP, YatesK, GordonYJ. Sequence changes in the human adenovirus" exact="type 5" post="DNA polymerase associated with resistance to the broad spectrum"/>
 <result pre="of cidofovir-resistant adenovirus variants in the New Zealand White rabbit" exact="ocular" post="model. Invest Ophthalmol Vis Sci. 2001;42(8):1812â€“1815.11431446 55.GrimleyMS, ChemalyRF, EnglundJA,"/>
 <result pre="et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and" exact="adult" post="allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase"/>
 <result pre="cell transplant recipients: a randomized placebo-controlled phase II trial. Biol" exact="Blood" post="Marrow Transplant. 2017;23(3):512â€“521. doi:10.1016/j.bbmt.2016.12.62128063938 56.AverbuchD, SafadiR, DarD, et al."/>
 <result pre="SafadiR, DarD, et al. Successful brincidofovir treatment of metagenomics-detected adenovirus" exact="infection" post="in a severely ill signal transducer and activator of"/>
 <result pre="of transcription-1-deficient patient. Pediatr Infect Dis J. 2019;38(3):297â€“299. doi:10.1097/INF.000000000000209029742642 57.2017" exact="American" post="transplant congress abstracts. Am J Transplant. 2017;17(Suppl 3):5â€“815. 58.GoossensPH,"/>
 <result pre="synovial fluid on adenovirus-mediated gene transfer to the synovial tissue." exact="Arthritis" post="Rheum. 2001;44(1):48â€“52. doi:10.1002/1529-0131(200101)44:1&amp;lt;48::AID-ANR7&amp;gt;3.0.CO;2-D11212175 59.NwanegboEC, RomanowskiEG, GordonYJ, GambottoA. Efficacy of"/>
 <result pre="RomanowskiEG, GordonYJ, GambottoA. Efficacy of topical immunoglobulins against experimental adenoviral" exact="ocular" post="infection. Invest Ophthalmol Vis Sci. 2007;48(9):4171â€“4176. doi:10.1167/iovs.07-049117724203 60.MartinT, DuffySF,"/>
 <result pre="natural autoantibodies. J Exp Med. 1992;175(4):983â€“991. doi:10.1084/jem.175.4.9831552291 61.OzturkHE, SonmezB, BedenU." exact="Corneal" post="sensitivity may decrease in adenoviral epidemic keratoconjunctivitisâ€“a confocal microscopic"/>
 <result pre="Eye Contact Lens. 2013;39(4):264â€“268. doi:10.1097/ICL.0b013e31828ef19b23719580 62.Meyer-rusenbergB, LoderstadtU, RichardG, KaulfersPM, GesserC." exact="Epidemic" post="keratoconjunctivitis: the current situation and recommendations for prevention and"/>
 <result pre="and treatment. Dtsch Arztebl Int. 2011;108(27):475â€“480. doi:10.3238/arztebl.2011.047521814523 63.KaufmanHE. Treatment of" exact="viral" post="diseases of the cornea and external eye. Prog Retin"/>
 <result pre="doi:10.3238/arztebl.2011.047521814523 63.KaufmanHE. Treatment of viral diseases of the cornea and" exact="external" post="eye. Prog Retin Eye Res. 2000;19(1):69â€“85. doi:10.1016/S1350-9462(99)00004-X10614681 64.HillenkampJ, ReinhardT,"/>
 <result pre="and without cyclosporin a 1% as a topical treatment of" exact="acute" post="adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002;109(5):845â€“850."/>
 <result pre="2002;109(5):845â€“850. doi:10.1016/S0161-6420(02)00992-211986086 65.HillenkampJ, ReinhardT, RossRS, et al. Topical treatment of" exact="acute" post="adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a"/>
 <result pre="65.HillenkampJ, ReinhardT, RossRS, et al. Topical treatment of acute adenoviral" exact="keratoconjunctivitis" post="with 0.2% cidofovir and 1% cyclosporine: a controlled clinical"/>
 <result pre="BaharI, SlomovicAR. Topical treatment with 1% cyclosporine for subepithelial infiltrates" exact="secondary" post="to adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638â€“640. doi:10.1097/ICO.0b013e3181c3303420458220 67.ReinhardT, GodehardtE, PfahlHG,"/>
 <result pre="67.ReinhardT, GodehardtE, PfahlHG, SundmacherR. [Local cyclosporin A in nummuli after" exact="keratoconjunctivitis" post="epidemica. A pilot study]. Ophthalmologe. 2000;97(11):764â€“768. German. doi:10.1007/s003470070025.11130165 68.KilicA,"/>
 <result pre="71.KoclukY, SukgenEA, CevherS, MatE. Symptomatic treatment of subepithelial infiltrates after" exact="viral" post="conjunctivitis: loteprednol or dexamethasone?Ocul Immunol Inflamm. 2017;25(5):649â€“653. doi:10.3109/09273948.2016.114959327015587 72.AsenaL,"/>
 <result pre="AltinorsDD. Comparison of clinical outcome with different treatment regimens in" exact="acute" post="adenoviral keratoconjunctivitis. Eye (Lond). 2017;31(5):781â€“787. doi:10.1038/eye.2017.428157224 73.GordonYJ, Araullo-cruzT, RomanowskiEG."/>
 <result pre="nonsteroidal anti-inflammatory drugs to steroid drops for control of post" exact="cataract" post="surgery inflammation. Oman J Ophthalmol. 2016;9(3):150â€“156. doi:10.4103/0974-620X.19226827843229 76.DunnJP. Uveitis."/>
 <result pre="Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes" exact="viral" post="shedding in experimental adenovirus models. Cornea. 2005;24(1):86â€“91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT,"/>
 <result pre="2005;24(1):86â€“91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT, YeeRW, WildJH. Topical cyclosporine therapy for ulcerative" exact="keratitis" post="associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109(5):610â€“612. doi:10.1016/S0002-9394(14)70704-42333932"/>
 <result pre="YeeRW, WildJH. Topical cyclosporine therapy for ulcerative keratitis associated with" exact="rheumatoid arthritis." post="Am J Ophthalmol. 1990;109(5):610â€“612. doi:10.1016/S0002-9394(14)70704-42333932 80.HollandEJ, OlsenTW, KetchamJM, et"/>
 <result pre="2006;151(12):2495â€“2501. doi:10.1007/s00705-006-0824-x16932984 90.Marrugal-lorenzoJA, Serna-gallegoA, Gonzalez-gonzalezL, et al. Inhibition of adenovirus" exact="infection" post="by mifepristone. Antiviral Res. 2018;159:77â€“83. doi:10.1016/j.antiviral.2018.09.01130268911 91.PelletierJS, StewartK, TrattlerW,"/>
 <result pre="2009;26(8):776â€“783. doi:10.1007/s12325-009-0062-119756415 92.KovalyukN, KaisermanI, MimouniM, et al. Treatment of adenoviral" exact="keratoconjunctivitis" post="with a combination of povidone-iodine 1.0% and dexamethasone 0.1%"/>
 <result pre="HaqueR. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for" exact="acute" post="viral conjunctivitis. Clin Ophthalmol. 2019;13:535â€“544. doi:10.2147/OPTH.S19127530962674 94.PintoRD, LiraRP, AbeRY,"/>
 <result pre="A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute" exact="viral" post="conjunctivitis. Clin Ophthalmol. 2019;13:535â€“544. doi:10.2147/OPTH.S19127530962674 94.PintoRD, LiraRP, AbeRY, et"/>
 <result pre="Dexamethasone/povidone eye drops versus artificial tears for treatment of presumed" exact="viral" post="conjunctivitis: a randomized clinical trial. Curr Eye Res. 2015;40(9):870â€“877."/>
 <result pre="doi:10.3109/02713683.2014.96441925310347 95.GonzalezG, YawataN, AokiK, KitaichiN. Challenges in management of epidemic" exact="keratoconjunctivitis" post="with emerging recombinant human adenoviruses. J Clin Virol. 2019;112:1â€“9."/>
 <result pre="MercoyrolL, CordaY, JobC, JobD. Accuracy of wheat-germ RNA polymerase II." exact="General" post="enzymatic properties and effect of template conformational transition from"/>
 <result pre="Eur J Biochem. 1992;206(1):49â€“58. doi:10.1111/ejb.1992.206.issue-11587282 102.Garcia-zalisnakD, RapuanoC, SheppardJD, DavisAR. Adenovirus" exact="ocular" post="infections: prevalence, pathology, pitfalls, and practical pointers. Eye Contact"/>
 <result pre="Ocul Pharmacol Ther. 2019;35(5):311â€“314. doi:10.1089/jop.2018.014530969148 104.SaedonH, NosekJ, PhillipsJ, NarendranN, YangYC." exact="Ocular" post="surface effects of repeated application of povidone iodine in"/>
 <result pre="WoldWS, TothK. Cidofovir and brincidofovir reduce the pathology caused by" exact="systemic" post="infection with human type 5 adenovirus in immunosuppressed Syrian"/>
 <result pre="TothK. Cidofovir and brincidofovir reduce the pathology caused by systemic" exact="infection" post="with human type 5 adenovirus in immunosuppressed Syrian hamsters,"/>
 <result pre="brincidofovir reduce the pathology caused by systemic infection with human" exact="type 5" post="adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely"/>
 <result pre="2014;112:38â€“46. doi:10.1016/j.antiviral.2014.10.00525453340 106.GordonYJ, NaesensL, DeClercqE, MaudgalPC, VeckeneerM. Treatment of adenoviral" exact="conjunctivitis" post="with topical cidofovir. Cornea. 1996;15(5):546. doi:10.1097/00003226-199609000-000188862935 107.KinchingtonPR, RomanowskiEG, Jerold"/>
 <result pre="111.Van GenechtenT, van HeerdenJ, BautersT, DhoogeC. Successful treatment of adenovirus" exact="infection" post="with brincidofovir in an immunocompromised patient after hematological stem"/>
 <result pre="NagaiS, SafwanM, et al. Brincidofovir as salvage therapy for adenovirus" exact="disease" post="in intestinal transplant recipients. Pharmacotherapy. 2018;38(4):470â€“475. doi:10.1002/phar.2018.38.issue-429457839 114.ChittickG, MorrisonM,"/>
 <result pre="brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol" exact="Blood" post="Marrow Transplant. 2019;25(2):369â€“381. doi:10.1016/j.bbmt.2018.09.03830292744 116.DanielBS, OrchardD. Ocular side-effects of"/>
 <result pre="cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369â€“381. doi:10.1016/j.bbmt.2018.09.03830292744 116.DanielBS, OrchardD." exact="Ocular" post="side-effects of topical corticosteroids: what a dermatologist needs to"/>
 <result pre="GungorSG. Effect of 0.05% topical cyclosporine for the treatment of" exact="symptomatic" post="subepithelial infiltrates due to adenoviral keratoconjunctivitis. Int J Ophthalmol."/>
 <result pre="121.SchultzC. Safety and efficacy of cyclosporine in the treatment of" exact="chronic" post="dry eye. Ophthalmol Eye Dis. 2014;6:37â€“42. doi:10.4137/OED.S1606725002818 122.LevingerE, TrivizkiO,"/>
 <result pre="122.LevingerE, TrivizkiO, ShacharY, LevingerS, TopicalVD. 0.03% tacrolimus for subepithelial infiltrates" exact="secondary" post="to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(5):811â€“816."/>
 <result pre="RodriguezM, Merayo-llovesJ, Alfonso SanchezJF. Topical tacrolimus for corneal subepithelial infiltrates" exact="secondary" post="to adenoviral keratoconjunctivitis. Cornea. 2017;36(9):1102â€“1105. doi:10.1097/ICO.000000000000127928704319 124.BarotRK, ShitoleSC, BhagatN,"/>
 <result pre="PatilK. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic" exact="ocular" post="diseases. J Clin Diagn Res. 2016;10(6):NC05â€“NC09. doi:10.7860/JCDR/2016/17847.7978"/>
</results>
